alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UN PUBLISHED
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 20
- 6481

ANTONIO MARCO HERRERA , Petitioner

- Appellant ,

v. HAROLD W. CLARKE , Respondent

- Appellee

.

Appeal from the United States District Court for the Eastern District of Virginia , at Alexandria

. Liam O’ Grady, Senior District Judge. ( 1:19

- cv
- 01301

- LO

- JFA )

Submitted : September 2 4 , 2020 Decided: September 29, 2020

Before HARRIS and RICHARDSON , Circuit Judges , and TRAXLER, Senior Circuit Judge.

Dismissed by un published per curiam opinion

.

Antonio Marco Herrera , Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM:
Antonio Marco Herrera seeks to appeal t he district court’s order denying without prejudice his motion to appoint counsel in his pending 28 U.S.C. § 2254 action

. This court may exercise jurisdiction only over final orders, 28 U.S.C. § 1291, and certain interlocutory
and collat eral orders, 28 U.S.C. § 1292; Fed. R. Civ. P. 54(b); Cohen v. Beneficial Indus. Loan Corp. , 337 U.S. 541, 545

- 46 (1949). The order Herrera seeks to appeal is neither a final order nor an appealable interlocutory or collateral order. Accordingly, we dism iss the appeal for lack of jurisdiction and deny Herrera’s motion for appointment of counsel on appeal and injunctive relief . We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before this cour t and argument would not aid the decisional process.
DISMISSED
§ 251.9 Registration of Foreign Sellers. ( a ) Any Foreign Seller(s) designated in a SIP Proposal must be registered with FDA before FDA will authorize the SIP Proposal.
( b ) To register, a Foreign Seller must provide the following information: ( 1 ) Name of the owner or operator; if a partnership, the name of each partner; if a corporation, the name of each corporate officer and director, and the place of incorporation;
( 2 ) All names of the Foreign Seller, including names under which the Foreign Seller conducts business or names by which the Foreign Seller is known;
( 3 ) Physical address and telephone number(s) of the Foreign Seller;
( 4 ) Registration number, if previously assigned by FDA;
( 5 ) A unique facility identifier in accordance with the system specified under section 510 of the Federal Food, Drug, and Cosmetic Act;
( 6 ) All types of operations performed by the Foreign Seller;
( 7 ) Name, mailing address, telephone number, and email address of the official contact for the establishment; and
( 8 ) Name, mailing address, telephone number, and email address of: ( i ) The U.S. agent;
( ii ) The Importer to which the Foreign Seller plans to sell eligible prescription drugs; and
( iii ) Each SIP Sponsor with which the Foreign Seller works.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             APR-01-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                           3,464
<SECURITIES>                                         0
<RECEIVABLES>                                   33,261
<ALLOWANCES>                                     1,139
<INVENTORY>                                          0
<CURRENT-ASSETS>                                39,558
<PP&E>                                          14,527
<DEPRECIATION>                                   6,836
<TOTAL-ASSETS>                                  48,496
<CURRENT-LIABILITIES>                           16,257
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        21,583
<OTHER-SE>                                       8,876
<TOTAL-LIABILITY-AND-EQUITY>                    48,496
<SALES>                                         32,279
<TOTAL-REVENUES>                                32,279
<CGS>                                           20,646
<TOTAL-COSTS>                                   20,646
<OTHER-EXPENSES>                                 9,194
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 107
<INCOME-PRETAX>                                  2,346
<INCOME-TAX>                                       915
<INCOME-CONTINUING>                              1,431
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,431
<EPS-BASIC>                                       0.11
<EPS-DILUTED>                                     0.11


</TABLE>
§ 524.1448 Mirtazapine transdermal ointment. ( a ) *Specifications.* Each gram of ointment contains 20 milligrams (mg) mirtazapine.
( b ) *Sponsor.* See No. 043264 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer topically by applying a 1.5 inch ribbon of ointment (approximately 2 mg) on the inner pinna of the cat's ear once daily for 14 days. Alternate the daily application of ointment between the left and right inner pinna of the ears.
( 2 ) *Indications for use.* For body weight gain in cats with a history of weight loss.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[83 FR 64740, Dec. 18, 2018, as amended at 85 FR 45308, July 28, 2020; 88 FR 16549, Mar. 20, 2023]
§ 169.181 Vanilla-vanillin flavoring. ( a ) Vanilla-vanillin flavoring conforms to the definition and standard of identity and is subject to any requirement for label statement of ingredients prescribed for vanilla-vanillin extract by § 169.180, except that its content of ethyl alcohol is less than 35 percent by volume.
( b ) The specified name of the food is “Vanilla-vanillin flavoring __-fold” or “__-fold vanilla-vanillin flavoring”, followed immediately by the statement “contains vanillin, an artificial flavor (or flavoring)”. The blank in the name is filled in with the whole number (disregarding fractions) expressing the sum of the number of units of vanilla constituent plus the number of ounces of added vanillin per gallon of the article. However, if the strength of the article is less than 2-fold, the term “__-fold” is omitted from the name.
[42 FR 14479, Mar. 15, 1977, as amended at 58 FR 2887, Jan. 6, 1993]
§ 526.313 Ceftiofur. ( a ) *Specifications.* Each single-dose, 10-milliliter syringe contains: ( 1 ) 125 milligrams (mg) ceftiofur equivalents as the hydrochloride salt; or
( 2 ) 500 mg ceftiofur equivalents as the hydrochloride salt.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.113 of this chapter.
( d ) *Conditions of use for syringe described in paragraph (a)(1) of this section in lactating cows* — ( 1 ) *Amount.* Infuse the contents of one syringe (125 mg ceftiofur equivalents) into each affected quarter. Repeat treatment in 24 hours. Once daily treatment may be repeated for up to 8 consecutive days.
( 2 ) *Indications for use.* For the treatment of clinical mastitis associated with coagulase-negative staphylococci, *Streptococcus dysgalactiae,* and *Escherichia coli;* and the treatment of diagnosed subclinical mastitis associated with coagulase-negative staphylococci and *S. dysgalactiae*.
( 3 ) *Limitations.* Milk taken from cows during treatment (a maximum of 8 daily infusions) and for 72 hours after the last treatment must not be used for human consumption. Following label use for up to 8 consecutive days, a 2-day preslaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 4 ) *Special considerations.* Federal law prohibits extralabel use of this drug in lactating dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food-producing species/production classes.
( e ) *Conditions of use for syringe described in paragraph (a)(2) of this section in dry cows* — ( 1 ) Amount . Infuse the contents of one syringe (500 mg ceftiofur equivalents) into each affected quarter at the time of dry off.
( 2 ) *Indications for use.* For the treatment of subclinical mastitis in dairy cattle at the time of dry off associated with *Staphylococcus aureus, Streptococcus dysgalactiae,* and *Streptococcus uberis*.
( 3 ) *Limitations.* Milk taken from cows completing a 30-day dry-off period may be used for food with no milk discard due to ceftiofur residues. Following intramammary infusion, a 16-day preslaughter withdrawal period is required for treated cows. No preslaughter withdrawal period is required for neonatal calves from treated cows regardless of colostrum consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 4 ) *Special considerations.* Federal law prohibits extralabel use of this drug in dry dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food-producing species/production classes.
[70 FR 9516, Feb. 28, 2005, as amended at 70 FR 20048, Apr. 18, 2005. Redesignated and amended at 71 FR 39545, July 13, 2006; 79 FR 10973, Feb. 27, 2013; 79 FR 18159, Apr. 1, 2014; 80 FR 34279, June 16, 2015; 86 FR 13185, Mar. 8, 2021]
I 

118TH CONGRESS 

2D SESSION H. R. 7459 

To amend the Pittman-Robertson Wildlife Restoration Act and the DingellJohnson Sport Fish Restoration Act to treat the District of Columbia 

the same as a State for purposes of such Acts, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 26, 2024 

Ms. NORTON introduced the following bill; which was referred to the 

Committee on Natural Resources 

A BILL 

To amend the Pittman-Robertson Wildlife Restoration Act 

and the Dingell-Johnson Sport Fish Restoration Act to 

treat the District of Columbia the same as a State for 

purposes of such Acts, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Pittman-Robertson 

5 Wildlife Restoration Act and Dingell-Johnson Sport Fish 

6 Restoration Act District of Columbia Equality Act of 

7 2024’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7459 IH

1 SEC. 2. TREATMENT OF DISTRICT OF COLUMBIA UNDER 

2 PITTMAN-ROBERTSON WILDLIFE RESTORA3 TION ACT AND DINGELL-JOHNSON SPORT 

4 FISH RESTORATION ACT. 

5 (a) PITTMAN-ROBERTSON WILDLIFE RESTORATION

6 ACT.—The Pittman-Robertson Wildlife Restoration Act 

7 (16 U.S.C. 669 et seq.) is amended— 

8 (1) in section 2, by redesignating paragraphs 

9 (6) through (11) as paragraphs (7) through (12), 

10 and by inserting after paragraph (5) the following: 

11 ‘‘(6) the term ‘State’ includes the District of 

12 Columbia;’’; and 

13 (2) in section 4— 

14 (A) by amending paragraph (1) of sub15 section (d) to read as follows: 

16 ‘‘(1) The Secretary of the Interior shall appor17 tion from the Wildlife Conservation and Restoration 

18 Account a sum equal to not more than one-fourth of 

19 1 percent thereof to each of Guam, American 

20 Samoa, the Virgin Islands, and the Commonwealth 

21 of the Northern Mariana Islands.’’; and 

22 (B) in subsection (e)(5), by striking ‘‘the 

23 District of Columbia,’’. 

24 (b) DINGELL-JOHNSON SPORT FISH RESTORATION

25 ACT.—The Dingell-Johnson Sport Fish Restoration Act 

26 (16 U.S.C. 777 et seq.) is amended— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 7459 IH

1 (1) in section 2— 

2 (A) by striking ‘‘and’’ at the end of para3 graph (2); 

4 (B) by striking the period at the end of 

5 paragraph (3) and inserting ‘‘; and’’; and 

6 (C) by adding at the end the following: 

7 ‘‘(4) the term ‘State’ includes the District of 

8 Columbia.’’; and 

9 (2) in section 12— 

10 (A) by striking ‘‘the Mayor of the District 

11 of Columbia,’’; 

12 (B) by striking ‘‘the District of Columbia,’’ 

13 the second and third place it appears; and 

14 (C) by striking ‘‘for the District of Colum15 bia one-third of 1 per centum,’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
#### § 338.3 Definition.

As used in this part:

*Nighttime sleep-aid.* A drug that is useful for the relief of occasional sleeplessness by individuals who have difficulty falling asleep.
U. S. Department of Homeland Security 

 Office for Domestic Preparedness

 Washington, D.C. 20531 

ODP Information Bulletin 

No. 106 March 25, 2004 

TO: All State Administrative Agency Heads 

 All State Administrative Agency Points of Contact 

FROM: C. Suzanne Mencer 

 Director 

SUBJECT: Fiscal Year 2004 Urban Areas Security Initiative Grant Program - 

 Allowable Training Costs for Transit System Personnel 

The purpose of this Bulletin is to expand the allowable training-related costs for transit 

system personnel under the FY 2004 Urban Areas Security Initiative (UASI) Grant 

Program. Allowable training-related costs include: 1) development and/or establishment 

of CBRNE training courses, which should be institutionalized within existing training

academies, universities or junior colleges. These courses must be consistent with ODP 

and Federal Transit Administration (FTA) prevention and response training guidelines 

and reviewed and approved by ODP; 2) overtime and backfill costs to replace personnel 

who are attending ODP-approved courses, to include those offered by the Transportation 

Safety Institute (TSI) and the National Training Institute (NTI) that are applicable to the 

purposes for which these grant funds were made available. 

The target audience for training courses funded under the FY 2004 UASI Program

includes transit system personnel with responsibilities for emergency preparedness and 

response, such as transit security officers, transit police, emergency managers, 

firefighters, emergency medical services personnel, transit system operators, maintenance 

workers, and managers. 

Questions related to this information bulletin may be directed to your ODP Preparedness 

Officer at (800) 368-6498. Thank you for your continued efforts and cooperation.
Wdesk | Exhibit






INSTRUMENT OF AMENDMENT TO THE
MDU RESOURCES GROUP, INC.
401(k) RETIREMENT PLAN




The MDU Resources Group, Inc. 401(k) Retirement Plan (as amended and restated January 1, 2017) (the “K‐Plan”), is hereby amended, effective January 1, 2017, as follows:




		
	1.
	By replacing the table in Section D-2-2 Eligibility to Share in the Retirement Contribution of Supplement D-2, Provisions Relating to the Retirement Contribution Feature for Certain Participating Affiliates, in its entirety, with the following:




	
			
	Participating Affiliate
	Current Effective Date (Original Effective Date)
	Retirement Contribution Amount - Percentage of Compensation

	Cascade Natural Gas Corporation (non-bargaining)
	January 1, 2011
(July 2, 2007)
	5%

	Cascade Natural Gas Corporation (Field Operations Bargaining Unit employees hired on or after 1/1/2007)
	May 1, 2015
(July 2, 2007)
	5%

	Great Plains Natural Gas Co.
	January 1, 2003
	5%

	Intermountain Gas Company
	January 1, 2011
(October 12, 2008)
	5%

	On Electric Group, Inc.
	March 7, 2011
	6%

	Rocky Mountain Contractors, Inc.
(non-bargaining)
	January 1, 2005
	5%

	WBI Energy Midstream, LLC1
	July 1, 2012
(January 1, 2001)
	5%






1The following participants of WBI Energy Midstream, LLC are excluded:, Grady Breipohl, Jon Forbes, Richard Guderjahn, Steven Haag, Raymond Harms, Wade Hasler, Douglas Henry, Pamela Lynn, Todd Mandeville, Marlin Mogan, and Dale Sudbrack due to participation in the appropriate pension plan replacement contribution.


Explanation: This amendment removes Fidelity Exploration & Production Company (“FEP”) as a Participating Affiliate in the Retirement Contribution Feature, effective January 1, 2017, as FEP no longer has any active employees participating in the K-Plan. 




		
	2.
	By replacing the first paragraph in Section D-6-2 Eligibility to Share in the Retirement Contribution of Supplement D-6, Provisions Relating to the MDU Resources Group, Inc. Retirement Contribution Feature, in its entirety, with the following:






1







		
	D-6-2
	Eligibility to Share in the Retirement Contribution. Participation in the Retirement Contribution for any Plan Year is limited to employees who are hired after December 31, 2005, and satisfy the Plan’s definition of Eligible Employee for the following Participating Affiliates:


	
	
	Knife River Corporation

	MDU Construction Services Group, Inc.

	MDU Resources Group, Inc.

	Montana-Dakota Utilities Co.

	WBI Energy, Inc.

	WBI Energy Transmission, Inc.






Explanation: This amendment removes Prairielands Energy Marketing, Inc. (“PEMI”) as a Participating Affiliate in the Retirement Contribution Feature, effective January 1, 2017, as PEMI no longer has any active employees participating in the K-Plan. 




IN WITNESS WHEREOF, MDU Resources Group, Inc., as Sponsoring Employer of the K-Plan, has caused this amendment to be duly executed by a member of the MDU Resources Group, Inc. Employee Benefits Committee on this 31st day of March, 2017.








	
	
	MDU RESOURCES GROUP, INC.

	EMPLOYEE BENEFITS COMMITTEE

	 

	 

	 

	By: /s/ Doran N. Schwartz

	Doran N. Schwartz, Chairman

	 








2
October 31, 2013

JUDGMENT

The Fourteenth Court of Appeals

NESTOR GOYTIA AS NEXT FRIEND FOR A.A.P., A CHILD, Appellant

NO. 14-13-00603-CV V.

VERONICA PAREDES AND ANGEL PAREDES, Appellees

________________________________

Today the Court heard appellant's motion to dismiss the appeal from the 

judgment signed by the court below on April 26, 2013. Having considered the 

motion and found it meritorious, we order the appeal DISMISSED.

We further order that all costs incurred by reason of this appeal be paid by 

appellant, Nestor Goytia.

We further order that mandate be issued immediately.

We further order this decision certified below for observance.
§ 522.2240 Sulfaethoxypyridazine. ( a ) *Specifications.* The drug is an aqueous solution of sulfaethoxypyridazine.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.650 of this chapter.
( d ) Conditions of use in cattle — ( 1 ) *Amount.* Administer 2.5 grams per 100 pounds of body weight per day by intravenous injection for not more than 4 days; or first treatment may be followed by 3 days of treatment with sulfaethoxypyridazine in drinking water or tablets in accordance with §§ 520.2240a(e) and 520.2240b(e) of this chapter.
( 2 ) *Indications for use.* For treatment of respiratory infection (pneumonia, shipping fever), foot rot, calf scours; as adjunctive therapy in septicemia accompanying mastitis and metritis.
( 3 ) *Limitations.* Do not treat within 16 days of slaughter. Milk that has been taken from animals during treatment and for 72 hours (6 milkings) after the latest treatment must not be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16196, Mar. 25, 2014]
§ 582.5920 Tyrosine. ( a ) *Product.* Tyrosine (L- and DL-forms).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
##### 



Exhibit 32.1
 CERTIFICATION PURSUANT TO RULE 13a-14(b) OF
THE SECURITIES EXCHANGE ACT OF 1934
  (1)
    
    the Report fully complies with the requirements of Section 13(a) of the Securities
Exchange Act of 1934, as amended; and
 (2)
    
    the information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.
 May 8, 2008
    By:
    /s/ Michael BrodskyMichael BrodskyChief Executive Officer May 8, 2008
    By:
    /s/ James A. BurkJames A. BurkChief Financial Officer
§ 582.1061 Lactic acid. ( a ) *Product.* Lactic acid.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 556.345 Ketoprofen. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of ketoprofen is 5 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for ketoprofen (marker residue) are: ( 1 ) *Cattle.* ( i ) Kidney (target tissue): 0.36 ppm.
( ii ) [Reserved]
( c ) *Related conditions of use.* See §§ 522.1225 and 522.2632 of this chapter.
[86 FR 61686, Nov. 8, 2021]
§ 573.1000 Verxite. The food additive verxite may be safely used in animal feed in accordance with the following prescribed conditions: ( a ) The additive is a magnesium-aluminum-iron silicate conforming to one of the following: ( 1 ) ( i ) Verxite granules: The additive contains a minimum of 98 percent of hydrobiotite; it is thermally expanded and has a bulk density of from 5 to 9 pounds per cubic foot.
( ii ) It is used or intended for use: ( a ) In poultry feed at a level not to exceed 5 percent of the weight of the finished feed as a nonnutritive bulking agent for restricting calorie intake in pullet replacement feeds.
( b ) As an anticaking or blending agent, pelleting aid, or nonnutritive carrier for the incorporation of nutrients in poultry, swine, dog, or ruminant feeds, in an amount not to exceed that necessary to accomplish its intended effect and in no case to exceed 1.5 percent of the dog feed or 5 percent of the final feed for other animals.
( 2 ) ( i ) Verxite flakes: The additive contains a minimum of 98 percent of hydrobiotite; it has a bulk density of from 20 to 30 pounds per cubic foot.
( ii ) It is used or intended for use as an anticaking or blending agent in ruminant feeds in an amount not to exceed that necessary to accomplish its intended effect and in no case to exceed 1 percent by weight of the final feed for ruminants.
( 3 ) ( i ) Verxite grits: The additive contains a minimum of 80 percent of hydrobiotite; it has a bulk density of from 40 to 50 pounds per cubic foot.
( ii ) It is used or intended for use as a partial roughage replacement in ruminant feeds in an amount not to exceed that necessary to accomplish its intended effect and in no case to exceed 1 percent by weight of the final feed.
( b ) To assure safe use of the additive, the label of any feed additive supplement, feed additive concentrate, feed additive premix, or complete feed prepared therefrom shall bear, in addition to the other information required by the Act, the name of the additive (verxite granules, verxite flakes, or verxite grits), adequate directions for use, and, when the additive is present in excess of 1 percent, a statement of the quantity of the additive contained therein and the term “nonnutritive” in juxtaposition therewith.
1 ... S ee T EX . R. A PP . P. 47. 4.
2 ... Th e t r i al cour t and t he di st r i ct cl er k’ s of f i ce have advi sed t hi s cour t t hat t h e y d o n o t h a v e a n y re c o r d t h a t r e la t o r h a s f ile d a p e n d in g m o t io n t o c o m p e l. Beca us e r el at or ’ s m ot i on ha s nev erbe en r ec ei ved by t he t r i al co ur t , Res ponde nt has notbe en pr ovi ded an oppo r t uni t y t o r ul e u pon t he m ot i on. Pr es ent m entof th e m o ti o n to th e tri a l c o u rt i s a p re re q u i s i te to m a n d a m u s re l i e f. See O’C onnor v. F ir s tC o u rto f

A pp e a ls , 8 3 7 S .W .2 d 9 4 , 9 7 (T e x . 1 9 9 2 ). 

## COURT OF APPEALS SEC OND DISTRICTOFTEXAS FORT WORTH NO. 2 - 08 - 49 1- CV I N R E DA NI E L HA R M ON R E L AT OR

----- ----- -- OR I GI NAL P R OCE E DI NG

----- ----- -- 

### M E M ORANDU M OP I NI ON 1

----- ----- -- T h e c o u r t h a s c o n s id e r e d r e la t o r ’s p e t it io n f o r w r it o f m a n d a m u s a n d is of t he opi ni on t hatr el i efs houl d be de ni ed. A cc or di ngl y, r el at or ’ s pet i t i on f or 2
w r i t of m and am us i s den i ed. R el at or shal l pay al l cost s of t hi s or i gi nal pr oceedi ng, f or w h ic h l et execut i on i ssue.

P E R CU R I AM2

P A N E L : M C C O Y a n d L IV IN G S T O N , J J . DEL I VERE D: J a nu a r y 20, 2009